Target Drug Exposure Attainment in Children: How to Get from Better to Best by Flint, R.B. (Robert) & Allegaert, K.M. (Karel)
Vol.:(0123456789)
Pediatric Drugs 
https://doi.org/10.1007/s40272-020-00402-6
COMMENTARY
Target Drug Exposure Attainment in Children: How to Get from Better 
to Best
Robert B. Flint1,2  · Karel Allegaert2,3,4 
 
© The Author(s) 2020
1 Introduction
The maturational physiology of children is reflected in more 
complex dosing regimens to attain target exposure through-
out pediatric life [1]. For multiple drugs, therapeutic drug 
monitoring (TDM) may support the optimization of phar-
macotherapy if the following requirements are met: (1) a 
narrow therapeutic range, (2) a large variability, (3) a known 
concentration–effect relationship, and (4) absence of meas-
urable effect. Model-informed precision dosing (MIPD), the 
next step for TDM, has recently gained more attention as 
it may serve as a powerful tool to help individualize dos-
ing [2]. In particular, pediatric pharmacotherapy may ben-
efit from the development of such clinical decision support 
(CDS) and move beyond complex dosing regimens to even 
more personalized dosing.
In this issue of the journal, Hartman et al. [3] evaluate tar-
get attainment during TDM of vancomycin, gentamicin, and 
tobramycin dosed according to model-based dosing guide-
lines for critically ill neonates and children. Despite this, the 
authors still observed a large proportion of both sub- and 
supratherapeutic concentrations for all three drugs. We very 
much appreciate their initiative in evaluating target attain-
ment following the implemented simplification of the more 
complex dosage regimen suggested in the published popu-
lation pharmacokinetic (PK) models [4, 5]. Their elegant 
design using data collected for TDM may be an inspiration 
for improved evaluation of pharmacotherapy for other drugs, 
as no additional burden was needed.
In this commentary, we would like to stress that such 
efforts are—at best—part of a target exposure improvement 
approach: how do we get from better to best? This relates 
to the “best target selection” and “best target attainment.”
2  Selection of the Best Target
Hartman et al. [3] used vancomycin trough concentrations 
as a surrogate target for an area under the plasma concen-
tration–time curve (AUC)0–24h > 400 to determine adequate 
therapy, although the target trough corresponding to an AUC 
0–24h of 400 depends on the dosing interval and individual 
clearance [6]. Allegaert et al. [7] illustrated that a certain 
daily dose for an AUC of  4000–24h divided by 12-, 8-, and 
6-h intervals corresponds to a trough steady state concentra-
tion of 11.3, 13.0, and 14.0 mg/L, respectively. Model-based 
estimations using Bayesian forecasting per patient would 
have allowed an evaluation based on AUC 0–24h instead of the 
surrogate target (trough concentrations). Nevertheless, the 
recommended vancomycin dosing regimen from the model-
ers did use AUC 0–24h > 400 as a target [4].
For aminoglycosides, a peak concentration of 8–10 times 
the minimum inhibitory concentration is considered the tar-
get for effectiveness, and a trough concentration < 1 mg/L 
(gentamicin) is the target for toxicity. Hartman et al. [3] ret-
rospectively collected data on drug administrations and peak 
and trough concentrations from electronic health records. 
The inaccurate registration of actions in clinical practice, 
such as exact time and duration of drug administration or 
sample collection, has a large impact on the quality and sub-
sequent interpretation of data. Given the rapidly changing 
concentration around time of peak concentration, errors in 
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registered collection times of ≥ 10 min have a large impact 
on the accuracy of interpretation. Evaluation of aminoglyco-
side toxicity based on collected trough concentrations may 
lead to adjusted dose intervals. De Hoog et al. [8] deter-
mined that the dose interval may be up to 48 h with main-
tained effectiveness so long as an adequate peak concentra-
tion is reached. However, the model-based dosing regimens 
by Valitalo et al. [5] suggested 60- and 72-h intervals for 
preterm neonates up to 10 days postnatal age and low birth-
weight < 2 kg. As the effectiveness of dose intervals > 48 h 
has not been investigated, TDM should be used to explore 
possible shortening of the dose interval to ≤ 48 h.
The study cohort of Hartman et  al. [3] was limited 
because of the criterion to include patients with samples 
collected at desired timepoints for peak or trough concentra-
tion and when steady state is reached. The combination of 
both allows straightforward comparison with reference target 
ranges. Therefore, 923 of 1642 patients were excluded as 
the measured concentration could not directly be compared 
to the target concentrations. The use of Bayesian forecast-
ing based on the measured concentrations in each patient 
(i.e., by estimating the trough concentration where a sample 
was collected too early) would have allowed the inclusion of 
more patients and the use of better targets for effectiveness 
for vancomycin (AUC 0–24h instead of trough concentrations).
Hartman et al. [3] considered steady state to be achieved 
3 half-lives after treatment start instead of 4–5 half-lives, as 
generally accepted. This may have overestimated the pro-
portion of subtherapeutic concentrations of vancomycin. 
Furthermore, steady state was based on the estimated half-
lives of vancomycin for infants and neonates described by 
Gross et al. [9] and De Hoog et al. [10], where clearance was 
only found to be predicted by postnatal age. Besides postna-
tal age, Janssen et al. [4] and Valitalo et al. [5] determined 
birthweight as a relevant covariate for clearance, which is 
in accordance with physiological intra- and extrauterine 
maturation. Hartman et al. [3] may have considered these 
more sophisticated descriptions of clearance for steady state 
determination, at least for (preterm) neonates.
3  Best Target Attainment
3.1  Model Translation to Dosages Fails to Catch 
the Full Spectrum
The Dutch Pediatric Formulary dosages for vancomycin, 
gentamicin, and tobramycin evaluated by Hartman et al. [3] 
were simplifications of the suggested dosages in the mod-
eling papers. However, the number of bodyweight-based 
dosage categories was reduced to arbitrary dichotomous 
suggestions (such as a given weight or age range), lead-
ing to larger ranges and variability in measured exposure. 
Furthermore, the suggested loading dose for vancomycin 
is not yet incorporated in the Dutch Pediatric Formulary. 
In particular, the smallest infants, and patients with renal 
impairment, have low clearance so require the most time 
to reach adequate exposure without a loading dose. We 
are aware that such simplification of dosing regimens may 
reduce prescribing errors and the risk of forgetting a dose 
adjustment for maturational effects, but therapy may be 
suboptimal. Unfortunately, hardly any electronic prescrib-
ing systems can currently incorporate complex dosing regi-
mens and guide programmed dose adjustments on patient 
characteristics reflecting maturation or disease progression. 
Safe and effective pharmacotherapy for children urgently 
demands the development and integration of software to 
accurately prescribe and adjust dosages and to incorporate 
MIPD and CDS.
Besides simplifications to facilitate clinical use of dosing 
regimens, omission of specific patient categories is relevant. 
As discussed by Hartman et al. [3], the population PK model 
by De Cock et al. excluded patients with severe renal dys-
function. Therefore, the subsequent dosing regimens may 
not be applied to patients with severe renal dysfunction. 
Although hemofiltration was an exclusion criterion for the 
cohort of Hartman et al. [3], patients with severe renal dys-
function were included and may have been responsible for 
the highest exposure and trough concentrations.
3.2  Model‑Informed Precision Dosing as the Road 
Ahead
MIPD can serve as a powerful tool to help individualize dos-
ing [2]. Bedside presentation of combined data on exposure 
and effect would allow quick/real-time individualization of 
dosing and target attainment. Frymoyer et al. [11] reported a 
successful adaptation of an incorporated Bayesian forecast-
ing tool for CDS on vancomycin therapy within the elec-
tronic health record. Unfortunately, such integration in elec-
tronic health records is currently only in development [12]. 
Using integrated CDS will minimize data translation errors, 
and data of predictors for the PK or pharmacodynamics may 
be continuously translated to suggested pharmacotherapy 
adjustments (e.g., creatinine for aminoglycosides and van-
comycin, postnatal age for maturational effect, interacting 
comedication such as nonsteroidal anti-inflammatory drugs 
on vancomycin clearance) [13]. This would require reliable 
registered data of clinical care, which may be achieved using 
scanning, automated checks, and bi-directional data transfer.
Clinical (pediatric) pharmacology is a multidisciplinary 
data science field that utilizes mathematical and statistical 
methods to generate maximal knowledge from data [14]. 
Pharmacometrics is a well-recognized tool to character-
ize disease progression, pharmacokinetics, and risk fac-
tors and can be incorporated in MIPD. Future research and 
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implementation initiatives should focus on the feasibility of 
integrating tools for model-informed individualized dosing 
in clinical practice.
Immediately implementable improvements may be to 
collect early samples upon start of treatment that can be 
forecasted using MIPD and allow prediction of an individual 
dosing regimen to attain steady state exposure within the tar-
get range. This would enable early optimization of treatment. 
For vancomycin, a trough sample may be collected before 
the second dose (even if the first dose was a loading dose) 
and targeted for AUC 0–24h > 400 using Bayesian forecasting. 
At the start of aminoglycoside therapy, sample collection 
depends on the situation. A sample may be drawn either a 
few hours before the next dose to predict a safe trough before 
continuation. We strongly recommend that all stakeholders 
embrace this opportunity to further tailor pharmacotherapy 
to the individual needs of our patients as an opportunity to 
“get from better to best.”
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